Fabio Stagno

Prolonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms

Chronic-phase chronic myeloid leukemia (CP-CML) is currently treated with tyrosine kinase inhibitors (TKIs), and the early achievement of cytogenetic and molecular milestones is strongly associated with improved clinical outcomes. Here, we describe the case of a 55-year-old woman...